Cero Therapeutics Holdings Inc., a Delaware-based company, announced on June 11, 2025, that it received a notification from Nasdaq regarding a failure to meet the minimum bid price requirement for its common stock. For 30 consecutive business days, the company's stock price remained below the $1.00 per share threshold mandated by Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Cero Therapeutics is not eligible for a compliance period due to previous reverse stock splits. In response, the company has requested a hearing before the Nasdaq Hearings Panel to contest the delisting decision. Additionally, the company executed a reverse stock split, effective June 13, 2025, at a 1-for-20 ratio, raising the stock price to $7.31 per share. However, there is no guarantee that this price level will be maintained or that the appeal will succeed, leaving the company's Nasdaq listing status uncertain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.